S-Alpha Therapeutics, Inc. collaborates with visiting delegationfrom Rohto Pharmaceutical Co., Ltd. for joint committee meeting
"Digital Health Expertise and Global Pharmaceutical Business Know-How Exchange, Pushing for Global Commercialization of DTx"
｜S-Alpha Therapeutics (“S-Alpha Therapeutics, Inc.”) initiates full-scale collaboration following the licensing out of its myopia DTx pipeline ‘SAT-001’ and strategic investment from Japan
｜Rohto (“Rohto Pharmaceutical Co., Ltd.”), with strong expertise in the ophthalmic market, visits S-Alpha Therapeutics to establish a joint committee for co-research and development initiatives
<Commemorative Photo of the S-Alpha Therapeutics and Rohto Joint Committee Formation and Visit Meeting.
Seung-eun Choi, CEO of S-Alpha Therapeutics (second from the left in the first row) and Tsuyoshi Ishii, Rohto Division manager (Third from the left in the first row).
Photo provided by S-Alpha Therapeutics>
S-Alpha Therapeutics, Inc. (CEO Seung-eun Choi) a digital health company, announced on 23rd that it had a meeting with the Joint Committee with Rohto, a Japan-based global pharmaceutical company. Rohto has visited Korea to collaborate on the research and development of S-Alpha Therapeutics' software as a medical device pipeline, 'SAT-001,' designed to slow the progression of myopia.
In March, S-Alpha Therapeutics and Rohto have entered into a strategic partnership for the commercialization of S-Alpha Therapeutics’ digital solution, SAT-001, in Japan and specific Asian countries.
S-Alpha Therapeutics aims to create synergy by combining its own digital health expertise with Rohto's knowledge of the ophthalmic disease and global myopia markets. The two companies have formed a joint committee as per their agreement and held their first joint committee meeting at S-Alpha Therapeutics' office in Seoul from Aug. 26th to the 28th. Discussions centered around joint research on SAT-001 and strategies for the commercialization of digital therapeutics (DTx) products in Korea, Japan, and other Asian countries. The companies plan to pursue R&D and commercialization of software as a medical device utilizing SAT-001 technology for both domestic and global markets.
